1
|
Zaytsev A, Dodd B, Magnani M, Ghiron C, Golding BT, Griffin RJ, Liu J, Lu X, Micco I, Newell DR, Padova A, Robertson G, Lunec J, Hardcastle IR. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach. Chem Biol Drug Des 2015; 86:180-9. [PMID: 25388787 DOI: 10.1111/cbdd.12474] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Revised: 09/18/2014] [Accepted: 10/15/2014] [Indexed: 12/19/2022]
Abstract
Two libraries of substituted benzimidazoles were designed using a 'scaffold-hopping' approach based on reported MDM2-p53 inhibitors. Substituents were chosen following library enumeration and docking into an MDM2 X-ray structure. Benzimidazole libraries were prepared using an efficient solution-phase approach and screened for inhibition of the MDM2-p53 and MDMX-p53 protein-protein interactions. Key examples showed inhibitory activity against both targets.
Collapse
Affiliation(s)
- Andrey Zaytsev
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK
| | - Barry Dodd
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK
| | - Matteo Magnani
- Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, Siena, 53100, Italy
| | - Chiara Ghiron
- Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, Siena, 53100, Italy
| | - Bernard T Golding
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK
| | - Roger J Griffin
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK
| | - Junfeng Liu
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Xiaohong Lu
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Iolanda Micco
- Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, Siena, 53100, Italy
| | - David R Newell
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Alessandro Padova
- Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, Siena, 53100, Italy
| | - Graeme Robertson
- Siena Biotech S.p.A., Strada del Petriccio e Belriguardo 35, Siena, 53100, Italy
| | - John Lunec
- Newcastle Cancer Centre, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
| | - Ian R Hardcastle
- Newcastle Cancer Centre, Northern Institute for Cancer Research and School of Chemistry, Newcastle University, Bedson Building, Newcastle upon Tyne, NE1 7RU, UK
| |
Collapse
|
2
|
Nencini A, Castaldo C, Comery TA, Dunlop J, Genesio E, Ghiron C, Haydar S, Maccari L, Micco I, Turlizzi E, Zanaletti R, Zhang J. Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor. Eur J Med Chem 2014; 78:401-18. [PMID: 24704613 DOI: 10.1016/j.ejmech.2014.03.031] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 02/10/2014] [Accepted: 03/11/2014] [Indexed: 11/29/2022]
Abstract
α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.
Collapse
Affiliation(s)
- Arianna Nencini
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy.
| | - Cristiana Castaldo
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Thomas A Comery
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - John Dunlop
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - Eva Genesio
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Chiara Ghiron
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Simon Haydar
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - Laura Maccari
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Iolanda Micco
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Elisa Turlizzi
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Riccardo Zanaletti
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Jean Zhang
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| |
Collapse
|
3
|
Zanaletti R, Bettinetti L, Castaldo C, Ceccarelli I, Cocconcelli G, Comery TA, Dunlop J, Genesio E, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Pratelli C, Scali C, Turlizzi E, Valacchi M. N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate. J Med Chem 2012; 55:10277-81. [PMID: 23083093 DOI: 10.1021/jm3013568] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
α7 Nicotinic acetylcholine receptors (α7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the α7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.
Collapse
Affiliation(s)
- Riccardo Zanaletti
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789). J Med Chem 2012; 55:4806-23. [PMID: 22468936 DOI: 10.1021/jm300247y] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Alpha-7 nicotinic acetylcholine receptors (α7 nAChR) are implicated in the modulation of many cognitive functions such as attention, working memory, and episodic memory. For this reason, α7 nAChR agonists represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort, around our previously reported chemical series, permitted the discovery of a novel class of α7 nAChR agonists with improved selectivity, in particular against the α3 receptor subtype and better ADME profile. The exploration of this series led to the identification of 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (25, SEN15924, WAY-361789), a novel, full agonist of the α7 nAChR that was evaluated in vitro and in vivo. Compound 25 proved to be potent and selective, and it demonstrated a fair pharmacokinetic profile accompanied by efficacy in rodent behavioral cognition models (novel object recognition and auditory sensory gating).
Collapse
Affiliation(s)
- Riccardo Zanaletti
- Siena Biotech SpA , Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology (Berl) 2011; 218:635-47. [PMID: 21643676 DOI: 10.1007/s00213-011-2357-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2011] [Accepted: 05/12/2011] [Indexed: 10/18/2022]
Abstract
RATIONALE α7 nicotinic acetylcholine receptor (nAChR) agonists are proposed as candidate agents for the adjunctive treatment of cognitive deficits associated with schizophrenia. Despite the pursuit of such an approach clinically, it is surprising that the preclinical profile of pro-cognitive agents in conjunction with antipsychotic drugs is currently unexplored. OBJECTIVES We determined if the memory-enhancing effects of the selective α7 nAChR agonist WYE-103914 were preserved in the presence of the atypical antipsychotic drug risperidone, and if the antipsychotic-like profile of risperidone was preserved in the presence of WYE-103914. METHODS Using the rat novel object recognition (NOR) paradigm, the maintenance of memory-enhancing activity of the α7 nAChR agonist WYE-103914 in the presence of risperidone was examined. Similarly, in the standard tests of antipsychotic-like activity, apomorphine-induced climbing (AIC) in mice and conditioned avoidance responding (CAR) in rats, the preservation of antipsychotic-like activity of risperidone was evaluated in the presence of WYE-103914. RESULTS WYE-103914 exhibited memory-enhancing activity in rat NOR, and this effect of WYE-103914 was retained in the presence of risperidone. In AIC, the atypical antipsychotic profile of risperidone was not significantly altered by WYE-103914. In contrast, WYE-103914 moderately potentiated the efficacy profile of risperidone in CAR, an effect that did not appear to be convincingly linked to a pharmacokinetic interaction. CONCLUSIONS These data underscore the value of a preclinical evaluation of the adjunctive profile of a memory-enhancing agent in combination with antipsychotics and provide further support to augmentation with α7 nAChR agonists to address the cognitive deficits associated with schizophrenia.
Collapse
Affiliation(s)
- Karen L Marquis
- Neuroscience Research Unit, Pfizer Global Research and Development, 445 Eastern Point Road, MS8220-4220, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Harrington PE, St Jean DJ, Clarine J, Coulter TS, Croghan M, Davenport A, Davis J, Ghiron C, Hutchinson J, Kelly MG, Lott F, Lu JYL, Martin D, Morony S, Poon SF, Portero-Larragueta E, Reagan JD, Regal KA, Tasker A, Wang M, Yang Y, Yao G, Zeng Q, Henley C, Fotsch C. The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core. Bioorg Med Chem Lett 2010; 20:5544-7. [PMID: 20708930 DOI: 10.1016/j.bmcl.2010.07.060] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2010] [Revised: 07/13/2010] [Accepted: 07/15/2010] [Indexed: 10/19/2022]
Abstract
The discovery of a series of novel and orally efficacious type II calcimimetics, developed from the lead compound 1, is described herein. Compound 22 suppressed plasma PTH levels relative to vehicle when dosed orally in a rat pharmacodynamic model.
Collapse
Affiliation(s)
- Paul E Harrington
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
Ghiron C, Haydar SN, Aschmies S, Bothmann H, Castaldo C, Cocconcelli G, Comery TA, Di L, Dunlop J, Lock T, Kramer A, Kowal D, Jow F, Grauer S, Harrison B, La Rosa S, Maccari L, Marquis KL, Micco I, Nencini A, Quinn J, Robichaud AJ, Roncarati R, Scali C, Terstappen GC, Turlizzi E, Valacchi M, Varrone M, Zanaletti R, Zanelli U. Novel Alpha-7 Nicotinic Acetylcholine Receptor Agonists Containing a Urea Moiety: Identification and Characterization of the Potent, Selective, and Orally Efficacious Agonist 1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) Urea (SEN34625/WYE-103914). J Med Chem 2010; 53:4379-89. [DOI: 10.1021/jm901692q] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Chiara Ghiron
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Simon N. Haydar
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Suzan Aschmies
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Hendrick Bothmann
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Cristiana Castaldo
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | | | - Thomas A. Comery
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Li Di
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - John Dunlop
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Tim Lock
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Angela Kramer
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Dianne Kowal
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Flora Jow
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Steve Grauer
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Boyd Harrison
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Salvatore La Rosa
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Laura Maccari
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Karen L. Marquis
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Iolanda Micco
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Arianna Nencini
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Joanna Quinn
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Albert J. Robichaud
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, New Jersey 08543-8000
| | - Renza Roncarati
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Carla Scali
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Georg C. Terstappen
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Elisa Turlizzi
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Michela Valacchi
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Maurizio Varrone
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Riccardo Zanaletti
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Ugo Zanelli
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| |
Collapse
|
9
|
Pasquini S, Mugnaini C, Brizzi A, Ligresti A, Di Marzo V, Ghiron C, Corelli F. Rapid Combinatorial Access to a Library of 1,5-Disubstituted-3-indole-N-alkylacetamides as CB2 Receptor Ligands. ACTA ACUST UNITED AC 2009; 11:795-8. [DOI: 10.1021/cc9000955] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Valensin S, Ghiron C, Lamanna C, Kremer A, Rossi M, Ferruzzi P, Nievo M, Bakker A. KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer 2009; 9:196. [PMID: 19545421 PMCID: PMC2711111 DOI: 10.1186/1471-2407-9-196] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2008] [Accepted: 06/22/2009] [Indexed: 11/25/2022] Open
Abstract
Background Glioblastomas (GBM) are typically comprised of morphologically diverse cells. Despite current advances in therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with GBM remains poor. Unfortunately, most patients die within 2 years of diagnosis of their disease. Molecular abnormalities vary among individual patients and also within each tumor. Indeed, one of the distinguishing features of GBM is its marked genetic heterogeneity. Due to the brain location of the tumor, the potential target inhibition for anticancer therapy must exhibit a manageable neurotoxicity profile in the concentration range in which the compounds show anti-proliferative activity. Kinesin KIF11 inhibition by small molecules such as Monastrol or Ispinesib is currently under investigation in the field of malignant tumors. In the current study we have assessed the relevance of the anti-mitotic Kinesin-like protein KIF11 in human GBM cell-lines. Results In this study the target was validated using a set of well characterised and potentially specific small molecule inhibitors of KIF11: an ispinesib analog, Monastrol, a Merck compound and 3 simplified derivatives of the Merck compound. Following an in silico selection, those compounds predicted to bear a favorable BBB permeation profile were assessed for their phenotypic effect on cell lines derived both from primary (U87MG) as well as treated (DBTRG-05-MG) glioblastomas. For some compounds, these data could be compared to their effect on normal human astrocytes, as well as their neurotoxicity on primary rat cortical neurons. The ispinesib analogue 1 showed an anti-proliferative effect on GBM cell lines by blocking them in the G2/M phase in a concentration range which was shown to be harmless to primary rat cortical neurons. Furthermore, ispinesib analog increased caspase 3/7-induced apoptosis in U87MG cells. Conclusion In the area of cell cycle inhibition, KIF11 is critical for proper spindle assembly and represents an attractive anticancer target. Our results suggest that KIF11 inhibitors, when able to permeate the blood-brain-barrier, could represent an interesting class of anticancer drugs with low neurotoxic effects in the treatment of brain tumors.
Collapse
Affiliation(s)
- Silvia Valensin
- SienaBiotech S,P,A, Discovery Research, Strada di Petriccio Belriguardo 35, 53100 Siena, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J, Roncarati R, Scali C, Valacchi M, Varrone M, Zanaletti R. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorg Med Chem 2009; 17:5247-58. [PMID: 19515567 DOI: 10.1016/j.bmc.2009.05.040] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2009] [Revised: 05/08/2009] [Accepted: 05/14/2009] [Indexed: 10/20/2022]
Abstract
Alpha 7 nicotinic acetylcholine receptor (alpha(7) nAChR) agonists are promising therapeutic candidates for the treatment of cognitive impairment associated with a variety of disorders including Alzheimer's disease and schizophrenia. Alpha 7 nAChRs are expressed in brain regions associated with cognitive function, regulate cholinergic neurotransmission and have been shown to be down regulated in both schizophrenia and Alzheimer's disease. Herein we report a novel, potent small molecule agonist of the alpha 7 nAChR, SEN12333/WAY-317538. This compound is a selective agonist of the alpha(7) nAChR with excellent in vitro and in vivo profiles, excellent brain penetration and oral bioavailability, and demonstrates in vivo efficacy in multiple behavioural cognition models. The SAR and biological evaluation of this series of compounds are discussed.
Collapse
Affiliation(s)
- Simon N Haydar
- Chemical Sciences and Neuroscience Discovery Research, Wyeth Research, CN 8000, Princeton, NJ 08543-8000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 2009; 329:459-68. [PMID: 19223665 DOI: 10.1124/jpet.108.150094] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The alpha7 nicotinic acetylcholine receptor (nAChR) is a promising target for treatment of cognitive dysfunction associated with Alzheimer's disease and schizophrenia. Here, we report the pharmacological properties of 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide [SEN12333 (WAY-317538)], a novel selective agonist of alpha7 nAChR. SEN12333 shows high affinity for the rat alpha7 receptor expressed in GH4C1 cells (K(i) = 260 nM) and acts as full agonist in functional Ca(2+) flux studies (EC(50) = 1.6 microM). In whole-cell patch-clamp recordings, SEN12333 activated peak currents and maximal total charges similar to acetylcholine (EC(50) = 12 microM). The compound did not show agonist activity at other nicotinic receptors tested and acted as a weak antagonist at alpha3-containing receptors. SEN12333 treatment (3 mg/kg i.p.) improved episodic memory in a novel object recognition task in rats in conditions of spontaneous forgetting as well as cognitive disruptions induced via glutamatergic [5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate); MK-801] or cholinergic (scopolamine) mechanisms. This improvement was blocked by the alpha7-selective antagonist methyllycaconitine, indicating that it is mediated by alpha7 activation. SEN12333 also prevented a scopolamine-induced deficit in a passive avoidance task. In models targeting other cognitive domains, including attention and perceptual processing, SEN12333 normalized the apomorphine-induced deficit of prepulse inhibition. Neuroprotection of SEN12333 was demonstrated in quisqualate-lesioned animals in which treatment with SEN12333 (3 mg/kg/day i.p.) resulted in a significant protection of choline acetyltransferase-positive neurons in the lesioned hemisphere. Cumulatively, our results demonstrate that the novel alpha7 nAChR agonist SEN12333 has procognitive and neuroprotective properties, further demonstrating utility of alpha7 agonists for treatment of neurodegenerative and cognitive disorders.
Collapse
|
13
|
Rivara M, Baheti AR, Fantini M, Cocconcelli G, Ghiron C, Kalmar CL, Singh N, Merrick EC, Patel MK, Zuliani V. 2,4(5)-Diarylimidazoles: Synthesis and biological evaluation of a new class of sodium channel blockers against hNav1.2. Bioorg Med Chem Lett 2008; 18:5460-2. [DOI: 10.1016/j.bmcl.2008.09.036] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2008] [Revised: 09/05/2008] [Accepted: 09/06/2008] [Indexed: 10/21/2022]
|
14
|
Piras L, Genesio E, Ghiron C, Taddei M. Scaffold Preparation and Parallel Synthesis of Arrays of 5,6,7,8-Tetrahydropyrrolo-azepinones in the Solution Phase. European J Org Chem 2008. [DOI: 10.1002/ejoc.200701024] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
15
|
Avramova S, Galletti E, Renzulli M, Giorgi G, Sgaragli G, Alderighi D, Ghiron C, Corelli F, Radi M, Botta M. Synthesis of an Original Oxygenated Taxuspine X Analogue: a Versatile “Non-Natural” Natural Product with Remarkable P-gp Modulating Activity. ChemMedChem 2008; 3:745-8. [DOI: 10.1002/cmdc.200700337] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
16
|
|
17
|
Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CGP. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem 2008; 51:1637-48. [PMID: 18278858 DOI: 10.1021/jm701095m] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Lck, or lymphocyte specific kinase, is a cytoplasmic tyrosine kinase of the Src family expressed in T-cells and NK cells. Genetic evidence from knockout mice and human mutations demonstrates that Lck kinase activity is critical for T-cell receptor-mediated signaling, leading to normal T-cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T-cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the structure-guided design, synthesis, structure-activity relationships, and pharmacological characterization of 2-amino-6-phenylpyrimido[5',4':5,6]pyrimido[1,2- a]benzimidazol-5(6 H)-ones, a new class of compounds that are potent inhibitors of Lck. The most promising compound of this series, 6-(2,6-dimethylphenyl)-2-((4-(4-methyl-1-piperazinyl)phenyl)amino)pyrimido[5',4':5,6]pyrimido-[1,2- a]benzimidazol-5(6 H)-one ( 25), exhibits potent inhibition of Lck kinase activity. This activity translates into inhibition of in vitro cell-based assays and in vivo models of T-cell activation and arthritis, respectively.
Collapse
Affiliation(s)
- Matthew W Martin
- Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
|
19
|
Micco I, Nencini A, Quinn J, Bothmann H, Ghiron C, Padova A, Papini S. Parallel synthesis of a series of potentially brain penetrant aminoalkyl benzoimidazoles. Bioorg Med Chem 2007; 16:2313-28. [PMID: 18078760 DOI: 10.1016/j.bmc.2007.11.068] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2007] [Revised: 11/16/2007] [Accepted: 11/23/2007] [Indexed: 01/16/2023]
Abstract
Alpha7 agonists were identified via GOLD (CCDC) docking in the putative agonist binding site of an alpha7 homology model and a series of aminoalkyl benzoimidazoles was synthesised to obtain potentially brain penetrant drugs. The array was prepared starting from the reaction of ortho-fluoronitrobenzenes with a selection of diamines, followed by reduction of the nitro group to obtain a series of monoalkylated phenylene diamines. N,N'-Carbonyldiimidazole (CDI) mediated acylation, followed by a parallel automated work-up procedure, afforded the monoacylated phenylenediamines which were cyclised under acidic conditions. Parallel work-up and purification afforded the array products in good yields and purities with a robust parallel methodology which will be useful for other libraries. Screening for alpha7 activity revealed compounds with agonist activity for the receptor.
Collapse
Affiliation(s)
- Iolanda Micco
- Siena Biotech S.p.A., Therapeutic Research, Via Fiorentina 1, Siena 53100, Italy
| | | | | | | | | | | | | |
Collapse
|
20
|
Cocconcelli G, Diodato E, Caricasole A, Gaviraghi G, Genesio E, Ghiron C, Magnoni L, Pecchioli E, Plazzi PV, Terstappen GC. Aryl azoles with neuroprotective activity--parallel synthesis and attempts at target identification. Bioorg Med Chem 2007; 16:2043-52. [PMID: 18024137 DOI: 10.1016/j.bmc.2007.10.090] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2007] [Revised: 10/23/2007] [Accepted: 10/30/2007] [Indexed: 11/19/2022]
Abstract
A parallel synthesis of aryl azoles with neuroprotective activity is described. All compounds obtained were evaluated in an in vitro assay using a NMDA toxicity paradigm showing a neuroprotective activity between 15% and 40%. The potential biological target of the active compounds was investigated by extensive literature searches based around similar scaffolds with reported neuroprotective activity. The most interesting molecules active in the NMDA toxicity assay (3a and 2g) showed moderate but significant activity in the inhibition of the Site 2 Sodium Channel binding assay at 10 microM. To confirm our hypothesis compounds 3a, c, f and 2g were tested in the Veratridine assay which is one of the excitotoxicity assays of relevance to NaV channels. The compounds tested showed an activity between 40% and 70%. The identification of neuroprotective small molecules and the identification of NaV channels as the potential site of action were the most important goals of this work.
Collapse
|
21
|
Abstract
A simple and efficient approach to selectively obtain 2,4(5)-diarylimidazoles suppressing formation of 2-aroyl-4(5)-arylimidazoles is described. The yield of each of the two products strongly depends on the reaction conditions employed. This reaction provides a simple method to prepare small libraries of biologically active compounds by parallel synthesis.
Collapse
Affiliation(s)
- Valentina Zuliani
- Dipartimento Farmaceutico, UniversitA degli Studi di Parma, V. le G.P. Usberti, 27/A, I-43100 Parma, Italy
| | | | | | | | | |
Collapse
|
22
|
Semeraro T, Lossani A, Botta M, Ghiron C, Alvarez R, Manetti F, Mugnaini C, Valensin S, Focher F, Corelli F. Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity. J Med Chem 2006; 49:6037-45. [PMID: 17004717 DOI: 10.1021/jm060547+] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A set of deazaguanine derivatives 1-3 targeting human purine nucleoside phosphorylase (hPNP) have been designed and synthesized. The new compounds are characterized by the presence of a structurally simplified "azasugar" motif to be more easily accessible by chemical synthesis than previous inhibitors. In the enzymatic assays, some of the new derivatives proved to be able to inhibit hPNP at low nanomolar concentration, thereby showing the same inhibitory potency in vitro as immucillin-H (IMH). Molecular docking experiments revealed a binding mode to hPNP essentially identical to that of IMH. As a result, the lower in vivo activity exhibited by 1d, compared with that exhibited by IMH, might be ascribed to differences in the pharmacokinetic, rather than pharmacodynamic, profile between these compounds. Derivatives 1a, 1d, and 2c emerged as the most active compounds within this new set and may represent interesting leads in the search for novel hPNP inhibitors.
Collapse
Affiliation(s)
- Teresa Semeraro
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via A. De Gasperi 2, 53100 Siena, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Martin MW, Newcomb J, Nunes JJ, McGowan DC, Armistead DM, Boucher C, Buchanan JL, Buckner W, Chai L, Elbaum D, Epstein LF, Faust T, Flynn S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Lee JH, Metz D, Middleton S, Mohn D, Morgenstern K, Morrison MJ, Novak PM, Oliveira-dos-Santos A, Powers D, Rose P, Schneider S, Sell S, Tudor Y, Turci SM, Welcher AA, White RD, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Amouzegh P, Ermann M, Jenkins J, Johnston D, Napier S, Power E. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem 2006; 49:4981-91. [PMID: 16884310 DOI: 10.1021/jm060435i] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and NK cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. A small molecule inhibitor of Lck is expected to be useful in the treatment of T cell-mediated autoimmune and inflammatory disorders and/or organ transplant rejection. In this paper, we describe the synthesis, structure-activity relationships, and pharmacological characterization of 2-aminopyrimidine carbamates, a new class of compounds with potent and selective inhibition of Lck. The most promising compound of this series, 2,6-dimethylphenyl 2-((3,5-bis(methyloxy)-4-((3-(4-methyl-1-piperazinyl)propyl)oxy)phenyl)amino)-4-pyrimidinyl(2,4-bis(methyloxy)phenyl)carbamate (43) exhibits good activity when evaluated in in vitro assays and in an in vivo model of T cell activation.
Collapse
Affiliation(s)
- Matthew W Martin
- Department of Chemistry Research and Discovery, Amgen Inc., One Kendall Square, Building 1000, Cambridge, Massachusetts 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
|
25
|
Antolini M, Bozzoli A, Ghiron C, Kennedy G, Rossi T, Ursini A. Analogues of 4,5-bis(3,5-dichlorophenyl)-2-trifluoromethyl-1H-imidazole as potential antibacterial agents. Bioorg Med Chem Lett 1999; 9:1023-8. [PMID: 10230632 DOI: 10.1016/s0960-894x(99)00112-2] [Citation(s) in RCA: 147] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A preliminary exploration of analogues of 4,5-bis(3,5-dichlorophenyl)-2-trifluoromethyl-1H-imidazole, 1, as novel antibacterial agents was carried out to determine the basic features of the structure responsible for the observed biological activity. The presence of two aryl rings, the imidazole NH and either a good electron withdrawing group or an aldehyde or amino group at C-2 were required for good levels of activity against methicillin resistant Staphylococcus aureus (MRSA).
Collapse
Affiliation(s)
- M Antolini
- GlaxoWellcome SpA, Medicines Research Centre, Verona, Italy
| | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Ghiron C, Piga E, Rossi T, Tamburini B, Thomas RJ. The stereoselective synthesis of a key intermediate of the trinem antibiotic sanfetrinem. Tetrahedron Lett 1996. [DOI: 10.1016/0040-4039(96)00682-x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Abstract
The decay of the indole triplet of single tryptophan-containing proteins and model compounds can be readily determined at room temperature in solution by monitoring the triplet absorption or emission following an exciting laser pulse. The dioxygen triplet quenching constants, can be measured for all these molecules and compared to the analogous singlet values determined by fluorescence methods. The dioxygen triplet quenching constant (tkq) ranged from a high of 5.1.10(9) M-1.s-1 for the exposed indole of corticotropin to a low of 0.1.10(9) M-1.s-1 for the buried indole of asparaginase. The ratio of these values with their respective dioxygen singlet quenching constants (skq), tkq/skq, ranged from 0.3 to 0.6 for aqueous exposed polypeptide indoles. For globular proteins the tkq/skq value is observed to be 0.2 +/- 0.1. This lower value for protein indoles is not attributable to 'bulk' environmental or hydrogen bonding effects, since the magnitude of tkq/skq (= 0.5 +/- 0.1) for model indoles was independent of solvent dielectric constant, polarity, and proticity. Temperature-dependence studies were done to test whether tkq could be used to characterize the nature of the protein matrix. The activation energy (Ea) for tkq was found to be 11 +/- 2 kcal/mol for most proteins. This Ea was independent of whether the indole side-chain was solvent exposed or buried in the non-aqueous protein interior. Large Ea values were also obtained for model indoles, naphthalene and nalidixic acid, dissolved in water, whereas the same compounds dissolved in 95% ethanol exhibited much smaller Ea values. These data, in combination with the observation that the tkq of model indoles is insensitive to changes in solvent viscosity, indicate that dioxygen quenching at the triplet level can not be easily used to characterize the dynamics of proteins.
Collapse
Affiliation(s)
- C Ghiron
- Department of Biochemistry, University of Missouri, Columbia 65211
| | | | | |
Collapse
|
29
|
|
30
|
Ghiron C, Bazin M, Santus R. Characterization of the indole triplet excited state in proteins utilizing laser flash photolysis. J Biochem Biophys Methods 1988; 15:337-48. [PMID: 3379247 DOI: 10.1016/0165-022x(88)90087-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The triplet-triplet absorption spectrum of the sole indole side chain of human serum albumin and its decay kinetics were previously characterized, at room temperature, by using a conventional flash photolysis method [(1978) Proc. Natl. Acad. Sci. USA 75, 1172-1175]. Exploitation of this potentially useful long lived reporter group in protein studies was limited by the excessively large sample size required by that apparatus. The 265 nm laser flash instrument used in the present work avoids this problem at the price of a loss in photo-selectivity. We report that the latter concern can be mitigated. Melittin was studied first because this polypeptide contains a single aromatic residue (W-19), and because its monomeric and tetrameric forms are good models for solvent exposed and buried indole side chains of proteins. For both forms, the indole triplet and neutral radical absorption spectra could be readily time resolved and identified on the basis of shape and differential dioxygen sensitivity. The single tryptophan containing protein human serum albumin was studied next because it contains a large number of other 265 nm absorbing moieties whose transient spectra might complicate the detection of the indole triplet. These transients were shown to not interfere significantly in the wavelength region 450 nm to 600 nm, and, in contrast to the indole triplet, they were relatively dioxygen insensitive. Thus, a facile means is available by which the indole triplet of proteins may be characterized. Subsequently the question of whether this species could be detected in the presence of nuclei acid components was investigated by flashing the phage fd. The putative nucleic acid transients were shown not to interfere and the absorbance of the indole triplet was readily time resolved. The spectral assignment was persuasively confirmed by showing that the indole triplet absorption and phosphorescence emission spectra decay with the same lifetime. The present work thus provides additional evidence for the general applicability of the indole triplet excited state as a long lived intrinsic protein reporter group.
Collapse
Affiliation(s)
- C Ghiron
- Department of Biochemistry, University of Missouri, Columbia 65211
| | | | | |
Collapse
|
31
|
Affiliation(s)
- E L Forker
- Department of Physiology, School of Medicine, University of Missouri, Columbia 65212
| | | |
Collapse
|